ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
13 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Group PLC Update on Allergy test menu (4455U)

25/11/2019 7:00am

UK Regulatory


Omega Diagnostics (LSE:ODX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Omega Diagnostics Charts.

TIDMODX

RNS Number : 4455U

Omega Diagnostics Group PLC

25 November 2019

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Update on Allergy test menu

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its first allergy screening assay to be run on the IDS-iSYS automated instrument.

The assay uses a mix of five different single allergens and is the first mix in a planned programme to develop a range of mixes to meet market needs. Screening assays, which contain multiple allergens, are a useful tool in helping to efficiently diagnose the causes of patient allergies.

Colin King, CEO of the Company, said: "The Grass mix is the first of five mixes required to enhance our Allergy panel and further demonstrates our excellent development capability. We will continue to focus our efforts to bring the remaining assays to the market, which will allow us to be more commercially competitive."

Contacts:

 
 Omega Diagnostics Group PLC                                  Tel: 01259 763 030 
 Bill Rhodes, Interim Non-Executive                     www.omegadiagnostics.com 
  Chairman 
  Colin King, Chief Executive 
 Kieron Harbinson, Group Finance 
  Director 
 
 finnCap Ltd                                                  Tel: 020 7220 0500 
 Geoff Nash/Hannah Boros (Corporate 
  Finance) 
 Camille Gochez (ECM) 
 
 Walbrook PR Limited                  Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                 Mob: 07980 541 893 
 Lianne Cawthorne                                             Mob: 07584 391 303 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDPGGCWGUPBGRC

(END) Dow Jones Newswires

November 25, 2019 02:00 ET (07:00 GMT)

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Your Recent History

Delayed Upgrade Clock